Immunotherapy for Gastroesophageal Cancer
Survival for patients with advanced oesophageal and stomach cancer is poor; together these cancers are responsible for more than a million deaths per year globally. As chemotherapy and targeted therapies such as trastuzumab and ramucirumab result in modest improvements in survival but not long-term...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-09-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2077-0383/5/10/84 |